Search the Newsreel

Humana Stock Gains 1.1% as 600,000-Member Medicare Reset Tests Its 2028 Margin Plan

Humana (NYSE:HUM) shares rose 1.1% last week as the company navigates a significant Medicare Advantage reset, planning to exit approximately 600,000 members while aiming to retain 40% in other offerings. This strategy is designed to achieve a sustainable pre-tax margin of at least 3% …

Kong Shum Smart Management Group (Holdings) Limited Revenue Breakdown – HKEX:8181

Indian Hume Pipe faces ₹63.1 lakh tax penalty on unexplained purchases

Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Humacyte (NASDAQ:HUMA) to a "strong sell" rating, though the broader analyst consensus remains a "Moderate Buy" with a $6.11 price target. The company reported a quarterly loss of $0.16 per share, missing estimates by $0.05, and revenue of $0.41 million, …

Humana, UnitedHealth trim Medicare Advantage on rising costs

Yahoo Finance Senior Columnist Kerry Hannon explains that major health insurers like Humana (HUM) and UnitedHealth Group (UNH) are dropping hundreds of thousands of Medicare Advantage members to protect profit margins as rising utilization drives up costs. Video Transcript 00:00 Josh Medicare Advantage popular …

Brokers Set Expectations for Humana's Q3 Earnings (NYSE:HUM)

Do Wall Street Analysts Like Humana Stock?

A colorful concept image of a scoring system_ Image by Who is Danny via Shutterstock_ Humana Inc. (HUM), headquartered in Louisville, Kentucky, provides medical and specialty insurance products. With a market cap of $46.7 billion, the company offers coordinated health care through health maintenance …

3,146 Shares in Humana Inc. $HUM Purchased by Retireful LLC

Retireful LLC recently acquired 3,146 shares of Humana Inc. (NYSE:HUM) for approximately $1.25 million, making it a new institutional investor in the company. Humana reported strong quarterly earnings, surpassing analyst expectations with $7.61 EPS and $40.89 billion in revenue, representing a 26.2% year-over-year increase. …

TriaGen Wealth Management LLC Purchases New Stake in Humana Inc. $HUM

TriaGen Wealth Management LLC has acquired a new stake in Humana Inc. (NYSE:HUM) during the second quarter, purchasing 3,039 shares valued at approximately $1,207,000. This comes as other institutional investors have also adjusted their holdings in the insurance provider. The article also details recent …

iHuman Inc. Sponsored ADR Class A Financial Disclosures & SEC Filings

Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW

This article focuses on the "Price to book forward" financial metric for Humacyte, Inc., traded on NASDAQ under the symbol HUMAW. It provides a snapshot of this financial data point within the context of the company's financial overview on a trading platform. The content …

CPI | Glenmark to Pay $15.3 Million to Settle Humana Antitrust Claims

Glenmark Pharmaceuticals' U.S. unit has agreed to pay $15.3 million to settle antitrust claims brought by Humana Inc., alleging price fixing and market allocation in the generic-drug industry. This settlement resolves three complaints as part of a broader litigation stretching back to 2016, and …

H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4

H.C. Wainwright has reiterated its Buy rating for Humacyte (HUMA.US), maintaining a price target of $4. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.

Can Humana Improve Caregiver Retention With HealthStream Deal?

Humana's Medicaid plan, Humana Healthy Horizons, is partnering with HealthStream in Indiana to enhance the home-care workforce by offering 1,000 Home Health Aide scholarships and deploying advanced training tools. This initiative aims to combat high caregiver turnover, with early results showing improved retention for …

Humana agrees not to reference Teva's Israel ties at US drug trial

Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company during an upcoming U.S. drug price-fixing trial. Teva had requested this, arguing that public views on the Gaza war could unfairly prejudice jurors. The agreement highlights the sensitivity of …

Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00

Benchmark has lowered its price target for Humacyte (NASDAQ:HUMA) to $1.00 from $2.00, while maintaining a "speculative buy" rating, implying a potential 51% upside. This adjustment comes after Humacyte missed Q2 earnings expectations, reporting a loss of $0.16 per share against an estimated $0.11 …

Equities Analysts Offer Predictions for Humana Q1 Earnings

Zacks Research has increased its Q1 2027 EPS estimate for Humana to $9.04, maintaining a "Hold" rating, with the full-year consensus at $9.09. Several other firms have also raised price targets or upgraded the stock, though MarketBeat's overall consensus remains "Hold" with an average …

Humana (NYSE:HUM) Downgraded by Zacks Research to "Hold"

Zacks Research has downgraded Humana (NYSE:HUM) from "strong buy" to "hold," projecting Q1 2027 earnings of $9.04 per share. This downgrade comes despite Humana exceeding recent quarterly expectations with EPS of $7.61 and revenue of $40.89 billion. Analyst sentiment remains mixed, with a consensus …

Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women

Humacyte (HUMA) announced stronger Phase 3 dialysis access data for its acellular tissue engineered vessel in female patients, outperforming the standard of care. The company plans to submit a supplemental Biologics License Application based on these results and has also received FDA acceptance for …

Authum Investment Shares Gain 2.56% on Nifty Midcap 150

Is Humacyte (HUMA) Undervalued Following Q2 2026 Earnings And Dialysis Trial Data?

Humacyte (HUMA) is in focus after its Q2 2026 earnings report, which showed modest revenue and a significant quarterly loss, compounded by a Nasdaq minimum bid price notice and interim Phase III dialysis trial data. Despite a fair value estimate of $4.00, suggesting it's …

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) reported a Q2 loss of $0.16 per share, missing the Zacks Consensus Estimate of a $0.1 loss, and revenues of $0.41 million, falling short of estimates by 70.79%. The company's shares have dropped 26.1% year-to-date, and it currently holds a Zacks …

Indian Hume Pipe Company standalone net profit rises 7.53% in the June 2026 quarter

Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk

Humacyte shares fall after Q2 revenue, EPS miss

Humacyte (HUMA [https://seekingalpha.com/symbol/HUMA]) shares fell 15% after the biotechnology company reported a wider-than-expected [https://seekingalpha.com/news/4631382-humacyte-gaap-eps-of--016-misses-by-006-revenue-of-041m-misses-by-07m] second-quarter loss and revenue below estimates. GAAP loss per share was $0.16, missing consensus by 6 cents, while revenue of $0.41 million fell $0.7 million short of expectations. Humacyte said …

Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results

The Indian Hume Pipe Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Humana stock (HUM) climbs 3% as 2027 COLA calculations obscure rising medical-cost shortfall

Humana (HUM) stock rose by 3% despite a preliminary 3.1% Social Security COLA for 2027, as the main concern for the Medicare insurer remains rising healthcare expenses, not retiree payments. The company's Q2 2026 results showed increased revenue and adjusted EPS, but a higher …

Humacyte Q2 Earnings Call Highlights

Humacyte reported its Q2 earnings, highlighting commercial sales growth for its SYMVESS product and plans for a supplemental BLA submission for dialysis access. The company also detailed positive interim data from its V012 Phase III trial for dialysis patients and announced the initiation of …

Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket

Humacyte missed analyst expectations for Q2 2026 revenue and EPS, causing its shares to fall over 10% in premarket trading. Despite the financial miss, the company highlighted progress in its commercial rebuild for SYMVESS, significant clinical trial results for its ATEV in dialysis access, …

Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M

Humacyte announced its second-quarter 2026 results, reporting product revenue of $0.4 million and a net loss of $36.8 million, with $80.3 million in cash. The company also shared positive interim Phase 3 results for its ATEV in female dialysis patients, planning a supplemental BLA …

Form 8K Humacyte Inc For: 12 August By Investing.com

This article from Investing.com announces that Humacyte Inc. has filed a Form 8K on August 12. The brief news item includes the company's stock symbol HUMA and notes its current price performance. No further details about the content of the Form 8K are provided.

Humacyte GAAP EPS of -$0.16 misses by $0.06, revenue of $0.41M misses by $0.7M

* Humacyte press release [https://seekingalpha.com/pr/20616207-humacyte-announces-second-quarter-2026-financial-results-and-provides-business-update] (HUMA [https://seekingalpha.com/symbol/HUMA]): Q2 GAAP EPS of -$0.16 misses by $0.06. * Revenue of $0.41M (+36.7% Y/Y) misses by $0.7M. MORE ON HUMACYTE * Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript [https://seekingalpha.com/article/4915163-humacyte-inc-huma-discusses-v012-study-top-line-results-for-engineered-vessel-in-dialysis] …